Format

Send to

Choose Destination
Transfus Apher Sci. 2016 Jun;54(3):345-55. doi: 10.1016/j.transci.2016.05.011. Epub 2016 May 13.

Donor lymphocyte infusion after allogeneic stem cell transplantation.

Author information

1
Programma Trapianto Humanitas Cancer Center, Istituto Clinico Humanitas, Rozzano, Italy. Electronic address: luca.castagna@humanitas.it.
2
Programma Trapianto Humanitas Cancer Center, Istituto Clinico Humanitas, Rozzano, Italy.
3
ASST-Monza, Ospedale San Gerardo, Apheresis Unit, Italy.

Abstract

Allogeneic stem cell transplantation (allo-SCT) is considered the cornerstone in the treatment of several malignant and not malignant hematological diseases. However, relapse of hematological disease after allo-SCT is considered the most challenging point in the field. The risk can be reduced through optimal patients, donor and disease selection before allo-SCT, but harnessing donor immune system is an appealing way to treat or avoid disease relapse. Donor lymphocyte infusion (DLI) is a simple and effective therapy after allo-SCT. In this paper, the efficacy of DLI will be analyzed in different hematological diseases, focusing also on their therapeutic or pre-emptive use.

KEYWORDS:

Allogeneic transplantation; DLI; Hematological disease; Pre-emeptive; Relapse

PMID:
27216544
DOI:
10.1016/j.transci.2016.05.011
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center